The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12D or KRAS G12V alteration.
 
Stephanie Yohay
No Relationships to Disclose
 
Grace Ying
No Relationships to Disclose
 
Elizabeth Auckley
No Relationships to Disclose
 
Mohammed Aldakkak
No Relationships to Disclose
 
Samih Thalji
No Relationships to Disclose
 
Parnian Vakili
No Relationships to Disclose
 
Justin Grahl
No Relationships to Disclose
 
Bradley Mayer
No Relationships to Disclose
 
Faisal Shahjehan
No Relationships to Disclose
 
Soon Khai Low
No Relationships to Disclose
 
Douglas Evans
No Relationships to Disclose
 
Kathleen Christians
No Relationships to Disclose
 
Yongwoo Seo
No Relationships to Disclose
 
Beth Erickson
No Relationships to Disclose
 
William Hall
Stock and Other Ownership Interests - Sonoptima
Consulting or Advisory Role - Aktis Oncology; Sonoptima
Research Funding - Elekta (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for a wearable device for radiation treatment planning (Inst)
Travel, Accommodations, Expenses - Elekta (Inst)
 
Thomas McFall
No Relationships to Disclose
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EOM Pharmaceuticals; Gaido; Iylon; LabCorp; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Prosperdtx; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
Other Relationship - Disclosures: Dr. Kurzrock has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Sysmex, Takeda, and TopAlliance a
 
Ben George
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Foundation Medicine; Ipsen; Roche/Genentech; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca; Taiho Oncology
Research Funding - CARsgen Therapeutics (Inst); GlycoNex (Inst); Helix BioPharma (Inst); Helix BioPharma (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Sirnaomics (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transcenta (Inst); Trishula Therapeutics (Inst); Tvardi Therapeutics (Inst)
 
Mandana Kamgar
Research Funding - Cornerstone Pharmaceuticals (Inst); OneCell Diagnostics India (Inst)